| Missing value estimation methods for DNA microarrays O Troyanskaya, M Cantor, G Sherlock, P Brown, T Hastie, R Tibshirani, ... Bioinformatics 17 (6), 520-525, 2001 | 4856 | 2001 |
| On the opportunities and risks of foundation models R Bommasani, DA Hudson, E Adeli, R Altman, S Arora, S von Arx, ... arXiv preprint arXiv:2108.07258, 2021 | 4190 | 2021 |
| Pharmacogenomics knowledge for personalized medicine M Whirl‐Carrillo, EM McDonagh, JM Hebert, L Gong, K Sangkuhl, ... Clinical Pharmacology & Therapeutics 92 (4), 414-417, 2012 | 2113 | 2012 |
| Doxorubicin pathways: pharmacodynamics and adverse effects CF Thorn, C Oshiro, S Marsh, T Hernandez-Boussard, H McLeod, ... Pharmacogenetics and genomics 21 (7), 440-446, 2011 | 2041 | 2011 |
| Estimation of the warfarin dose with clinical and pharmacogenetic data International Warfarin Pharmacogenetics Consortium New England Journal of Medicine 360 (8), 753-764, 2009 | 1868 | 2009 |
| Diversity of gene expression in adenocarcinoma of the lung ME Garber, OG Troyanskaya, K Schluens, S Petersen, Z Thaesler, ... Proceedings of the National Academy of Sciences 98 (24), 13784-13789, 2001 | 1673 | 2001 |
| Guidelines for investigating causality of sequence variants in human disease DG MacArthur, TA Manolio, DP Dimmock, HL Rehm, J Shendure, ... Nature 508 (7497), 469-476, 2014 | 1441 | 2014 |
| Personal omics profiling reveals dynamic molecular and medical phenotypes R Chen, GI Mias, J Li-Pook-Than, L Jiang, HYK Lam, R Chen, E Miriami, ... Cell 148 (6), 1293-1307, 2012 | 1410 | 2012 |
| The chemical genomic portrait of yeast: uncovering a phenotype for all genes ME Hillenmeyer, E Fung, J Wildenhain, SE Pierce, S Hoon, W Lee, ... Science 320 (5874), 362-365, 2008 | 1164 | 2008 |
| Principal components analysis to summarize microarray experiments: application to sporulation time series S Raychaudhuri, JM Stuart, RB Altman Biocomputing 2000, 455-466, 1999 | 1164 | 1999 |
| Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features KH Yu, C Zhang, GJ Berry, RB Altman, C Ré, DL Rubin, M Snyder Nature communications 7 (1), 12474, 2016 | 1018 | 2016 |
| Machine learning in chemoinformatics and drug discovery YC Lo, SE Rensi, W Torng, RB Altman Drug discovery today 23 (8), 1538-1546, 2018 | 975 | 2018 |
| Data-driven prediction of drug effects and interactions NP Tatonetti, PP Ye, R Daneshjou, RB Altman Science translational medicine 4 (125), 125ra31-125ra31, 2012 | 898 | 2012 |
| Clinical assessment incorporating a personal genome EA Ashley, AJ Butte, MT Wheeler, R Chen, TE Klein, FE Dewey, ... The Lancet 375 (9725), 1525-1535, 2010 | 818 | 2010 |
| A Bayesian framework for combining heterogeneous data sources for gene function prediction (in Saccharomyces cerevisiae) OG Troyanskaya, K Dolinski, AB Owen, RB Altman, D Botstein Proceedings of the National Academy of Sciences 100 (14), 8348-8353, 2003 | 801 | 2003 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing JA Johnson, L Gong, M Whirl‐Carrillo, BF Gage, SA Scott, CM Stein, ... Clinical Pharmacology & Therapeutics 90 (4), 625-629, 2011 | 781 | 2011 |
| Method for monitoring and/or modifying web browsing sessions RM Felciano, RB Altman US Patent 6,052,730, 2000 | 748 | 2000 |
| Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity PW Burridge, YF Li, E Matsa, H Wu, SG Ong, A Sharma, A Holmström, ... Nature medicine 22 (5), 547-556, 2016 | 728 | 2016 |
| Metformin pathways: pharmacokinetics and pharmacodynamics L Gong, S Goswami, KM Giacomini, RB Altman, TE Klein Pharmacogenetics and genomics 22 (11), 820-827, 2012 | 624 | 2012 |
| Structural bioinformatics J Gu, PE Bourne John Wiley & Sons, 2009 | 552 | 2009 |
